Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00356460 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma
A Phase 1 study of Melanoma and Carcinoma, Renal Cell, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
- 6
- Study locations
NCT00356460: Completed Phase 1 study of Melanoma and Carcinoma, Renal Cell, sponsored by Genzyme, a Sanofi Company.
NCT00356460 is a Phase 1 study of Melanoma and Carcinoma, Renal Cell that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 29 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (96% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00356460, a Phase 1 study of Melanoma and Carcinoma, Renal Cell, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of GC1008, a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in previously treated patients with locally advanced or metastatic renal cell carcinoma or malignant melanoma.
Conditions Studied
Interventions
- BIOLOGICAL GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody
Study Locations (6)
Massachusetts
- Dana Farber/Harvard Cancer Center, Dana Farber Cancer Institute - Boston
- Beth Israel Deaconess Medical Center - Boston
- Massachusetts General Hospital - Cambridge
Maryland
- National Cancer Institute (NCI) - Bethesda
New Jersey
- Cancer Institute of New Jersey - New Brunswick
Ohio
- Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2006-09 |
| Est. Completion | 2009-05 |
| Phase | Phase 1 |
What the finished NCT00356460 record still lists
NCT00356460 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody is the first listed.
NCT00356460 lists 6 locations in 4 states (Massachusetts, Maryland, New Jersey).
Frequently Asked Questions
What is clinical trial NCT00356460 about?
NCT00356460 is a clinical study titled "Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma". The purpose of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of GC1008, a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in previously treated patients with locally advanced or metastatic renal cell carcinoma or malignant melanoma.
What is the current status of trial NCT00356460?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2006-09. Estimated completion is 2009-05.
What conditions does trial NCT00356460 study?
This clinical trial studies the following conditions: Melanoma, Carcinoma, Renal Cell.
What interventions are being tested in trial NCT00356460?
The interventions under investigation include: GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody (BIOLOGICAL).
Who is sponsoring clinical trial NCT00356460?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00356460 being conducted?
This trial has 6 study locations across Maryland, Massachusetts, New Jersey, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00356460's enrollment target sits among peer trials
29 205th of 266 higher than 61 of 266 other Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia